Abstracts tagged "Inflammation"

Abstract Number: 0930 • ACR Convergence 2024
The Common Form of the Inflammatory Skin Disease Hidradenitis Suppurativa Is Associated with Low Nicastrin Expression in Dermal Fibroblasts
Kaitlin Williams, Beita Badiei, Hana Minsky and Luis Garza, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules and abscesses in intertriginous areas. Despite its increasing prevalence, the etiology…
Abstract Number: 1437 • ACR Convergence 2024
Impact of Early Diagnosis in Patients with Axial Spondyloarthritis on Arterial Stiffness Progression
Sze-Lok Lau¹, Huan Meng², Isaac Cheng¹, Bryan PY Yan¹, Alex PW Lee¹, Ho So¹ and Lai-shan Tam³, ¹The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²The Faculty of Medicine, CUHK, Hong Kong, China (People's Republic), ³The Chinese University of Hong Kong, New Territories, Hong Kong
Background/Purpose: In patients with axial spondyloarthritis (AxSpA), we have reported that higher inflammatory burden as reflected by a longer disease duration, delay in diagnosis and…
Abstract Number: 1793 • ACR Convergence 2024
SLE Patient Serum and SLE-associated Danger Signals Impair Efferocytosis in Human Macrophages
Jessica Shannon and Rafael de Queiroz Prado, AstraZeneca, Gaithersburg, MD
Background/Purpose: Efficient clearance of apoptotic cells, known as efferocytosis, plays a pivotal role in maintaining self-tolerance. Dysfunction in efferocytosis is implicated in the pathogenesis of…
Abstract Number: 2000 • ACR Convergence 2024
Induction of Systemic Inflammatory Diseases with Dupilumab Therapy
Jeanne Tisseau des Escotais¹, Camille Taille², Julie Merindol³, Matthieu Groh⁴, Perrine SMETS⁵, Amel Boudjemaa⁶, Alexandra Audemard⁷, Nabil Belfeki⁸, Philippe Bonniaud⁹, Chloe Comarmond¹⁰, Isabelle DELACROIX¹¹, Charlotte Descours¹², Lucile Grange¹³, Paul Legendre¹⁴, Nihal Martis¹⁵, Thomas Moulinet¹⁶, Béatrice Walls¹⁷, Laurent Chouchana¹ and Benjamin Terrier¹⁸, ¹Cochin, Paris, France, ²Bichat Hospital, Paris, France, ³Internal Medicine Department, University Hospital of Nice, Côte d'Azur University, Nice, Provence-Alpes-Côte d'Azur, France., Nice, France, ⁴Foch, Suresnes, France, ⁵Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ⁶CHU créteil, Créteil, France, ⁷Tours, Tours, France, ⁸CH Melun, Melun, France, ⁹Centre de Référence Constitutif des Maladies Pulmonaires Rares de l'Adulte, Service de Pneumologie et Soins Intensifs Respiratoires, Centre Hospitalo-Universitaire de Dijon-Bourgogne, Dijon, France, ¹⁰Lariboisière University Hospital, Paris, France, ¹¹CHI créteil, Créteil, France, ¹²CH Tours, Tours, France, ¹³CH Saint-Etienne, Saint-Etienne, France, ¹⁴Service Médecine Interne et Polyvalente, Centre Hospitaliers Le Mans, Le Mans, France, ¹⁵CH Nice, Nice, France, ¹⁶CHRU de Nancy, Vandœuvre-lès-Nancy, France, ¹⁷Paris, Paris, France, ¹⁸Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Dupilumab is a monoclonal antibody directed against the alpha subunit of the interleukin (IL)-4 receptor, blocking interleukin (IL)-4 and IL-13 signaling. It is approved…
Abstract Number: 2474 • ACR Convergence 2024
High-throughput Screening Identifies Specific Molecular Markers for ILD in Patients with Rheumatic Diseases
Anna-Maria Hoffmann-Vold¹, Vyacheslav Palchevskiy², Phuong Phuong Diep³, Henriette Didriksen¹, Mona Lovise Talaro Ramsli¹, Jin Zhou⁴, Shahrzad Lari⁴, Elena Pachera⁵, Michael T Durheim¹, Øyvind Molberg⁶, Oliver Distler⁷, S. Samuel Weigt² and John A Belperio⁴, ¹Oslo University Hospital, Oslo, Norway, ²University of California Los Angeles, Los Angeles, CA, ³Oslo University Hospital, Department of Respiratory Disease, Oslo, Norway, ⁴University of California Los Angeles, Los Angeles, ⁵University Hospital Zurich, Zurich, Switzerland, ⁶Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Molecular expression patterns of lung tissue across rheumatic musculoskeletal diseases (RMDs) have not been extensively studied. Lung sampling is invasive and not always practical…
Abstract Number: 2659 • ACR Convergence 2024
A Comprehensive Approach Utilizing a Combination of Genetics, Cytological Analysis, and Imaging Techniques to Speed up the Diagnostic Process in VEXAS Patients
Sara Bindoli¹, Chiara Baggio², Roberto Padoan³, Riccardo Bixio⁴, doria Andrea⁵, Roberta Ramonda² and Paolo Sfriso¹, ¹Rheumatology Unit, University of Padova, Italy, Padova, Veneto, Italy, ²Rheumatology Unit, University of Padova, Italy, Padova, Italy, ³Department of Medicine DIMED, Division of Rheumatology, University of Padua, Padua, Italy, ⁴University of Verona, Verona, Verona, Italy, ⁵University of Padova, Padova, Italy
Background/Purpose: VEXAS is a newly described “haemato-autoinflammatory” condition resulting from somatic mutations in the UBA-1 gene. By integrating genetics, cytology and imaging, this work seeks…
Abstract Number: L05 • ACR Convergence 2023
DICKENS: A Multicentre Randomised Controlled Trial of Diacerein for Knee Osteoarthritis with Effusion-Synovitis
Guoqi Cai¹, Graeme Jones², Flavia Cicuttini³, Anita Wluka³, Yuanyuan Wang³, Catherine Hill⁴, Helen Keen⁵, Benny Antony², barbara de Graaff², Michael Thompson², Tania Winzenberg², Kathy Buttigieg², Petr Otahal² and Dawn Aitken², ¹School of Public Health, Anhui Medical University, Hefei, China, ²Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Monash University, Melbourne, Australia, ⁴The Queen Elizabeth Hospital, University of Adelaide, Adelaide, Australia, ⁵Fiona Stanley Hospital, Murdoch, Australia
Background/Purpose: There is an unmet need for treatments of knee OA. Diacerein is recommended for alleviating pain in OA patients for its anti-inflammatory effect by…
Abstract Number: 0278 • ACR Convergence 2023
NOD2 Genotyping Landscape in Yao Syndrome
Hafsa Nomani¹, Ashmia Saif², Frank Hwang¹ and Qingping Yao¹, ¹Stony Brook University, Stony Brook, NY, ²Stony Brook University Hospital, Syosset, NY
Background/Purpose: Yao syndrome (YAOS, OMIM 617321) is formerly designated NOD2-associated autoinflammatory disease. A spectrum of NOD2 mutations have been associated with this disease. This study…
Abstract Number: 0756 • ACR Convergence 2023
Validation of Quantitative Effusion-synovitis Volume Measured by Deep-learning: Data from the Osteoarthritis Initiative
Banafshe Felfeliyan¹, Stephanie Wichuk², Abhilash Hareendranathan³, Janet Ronsky⁴ and Jacob Jaremko², ¹University of Alberta, Calgary, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Radiology and Diagnostic Imaging, Edmonton, AB, Canada, ⁴University of Calgary, Calgary, AB, Canada
Background/Purpose: Knee effusion-synovitis (ES) is an attractive target for therapeutic interventions in arthritis, since it is associated with stiffness, pain, and disease progression to arthroplasty.…
Abstract Number: 0947 • ACR Convergence 2023
Fcγ Receptors Define Pro-Phagocytic Macrophages and Trigger Pro-Inflammatory Responses in Patients with Systemic Sclerosis
Amela Hukara¹, Gino Andrea Bonazza¹, Tracy Tabib², Raphael Micheroli¹, Suzana Jordan³, Kristina Bürki¹, Sylvie Schlitz Schönbächler¹, Adrian Ciurea⁴, Oliver Distler³, Robert Lafyatis⁵, Przemyslaw Blyszczuk¹ and Gabriela Kania¹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁴University Hospital Zurich, Zürich, Switzerland, ⁵University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Fcy receptors (FcγR) are opsonic phagocytic receptors, requiring tight regulations to prevent uncontrolled activation of pro-inflammatory phagocytosis. SSc macrophages display an alternatively-activated profibrotic phenotype.…
Abstract Number: 1265 • ACR Convergence 2023
Changes in the Endocannabinoid Tone in Rheumatoid Arthritis and Osteoarthritis – Discovery of a Novel Target for the Treatment of Pain and Inflammation?
Jost Klawitter¹, Andrew Clauw¹, Jennifer Seifert¹, Jelena Klawitter¹, Bridget Tompson¹, Cristina Sempio¹, Uwe Christians¹ and Larry Moreland², ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Colorado, Denver, CO

Background/Purpose: Inflammation is a complicated physiological process that results in a variety of disorders. Several inflammatory mediators are produced during this process, which is responsible…
Abstract Number: 1725 • ACR Convergence 2023
Distinct Perivascular and Intravascular Lymphatic Mast Cells and Their Role in Lymphatic Clearance, Joint Inflammation, and Bone Erosion in the TNF-Transgenic Murine Arthritis Model
Yue Peng¹, H. Mark Kenney², Karen Bentley³, Lianping Xing⁴, Christopher T Ritchlin⁵ and Edward Schwarz³, ¹University of Rochester Medical Center, Rochester, NY, ²University of Rochester School of Medicine and Dentistry, Henrietta, NY, ³University of Rochester, Rochester, NY, ⁴University of Rochester Medical Center, Webster, NY, ⁵University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY
Background/Purpose: Inflammatory-erosive arthritis is exacerbated by lymphatic dysfunction (1), and mast cells (MCs) regulate lymphatic vessel contractions via release of inflammatory and vasoactive mediators (2).…
Abstract Number: 1779 • ACR Convergence 2023
A Novel Inhibitory Pathway of Synovial Inflammation Exerted by Glucocorticoids and TNF Inhibitors Through LAG-3 Up-Regulation
Smadar Gertel¹, Victoria Furer¹, Ari Polachek¹ and Ori Elkayam², ¹Tel Aviv Sourasky Medical center, Tel Aviv, Israel, ²Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated condition that results in systemic musculoskeletal (MSK) inflammation, including peripheral synovitis, enthesitis and axial involvement. Glucocorticoids (GCs)…
Abstract Number: 2238 • ACR Convergence 2023
Longitudinal Effect of Guselkumab on Biomarkers of Inflammation and Cardiovascular Risk in Bionaive Patients with Active Psoriatic Arthritis and High Systemic Inflammatory Burden: Post-hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-Controlled Study
Arthur Kavanaugh¹, Enrique Soriano², Jan Dutz³, Carlo Selmi⁴, Emmanouil Rampakakis⁵, Natalie shiff⁶, Francois Nantel⁷, Frederic Lavie⁸ and Laura Coates⁹, ¹Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ²Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Department of Dermatology and Skin Science, Vancouver General Hospital, Vancouver, BC, Canada, ⁴Rheumatology and Clinical Immunology, Humanitas Research Hospital / Internal Medicine, Humanitas University, Rozzano, Italy, ⁵McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁶Immunology, Janssen Scientific Affairs, LLC / Adjunct, Community Health and Epidemiology, University of Saskatchewan, Horsham, PA, ⁷Nantel Medsci Consult, Consultant, Montreal, QC, Canada, ⁸The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ⁹University of Oxford, Oxford, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) has been associated with an increased risk of cardiovascular (CV) disease, likely due to accelerated atherosclerosis secondary to chronic inflammation.1 As…
Abstract Number: 2571 • ACR Convergence 2023
Identification of Biomarkers Predicting Steroid Resistance in Immune Checkpoint Inhibitor-Induced Arthritis
Rashmi Thimmapuram¹, Maryam Buni², Huifang Lu³, Jean Tayar⁴, Yuanteng Li⁴, Maria Suarez-Almazor⁵, Rene Rico⁴, Naimah Turner⁴, Roza Nurieva⁴ and Sang Kim⁶, ¹Baylor College of Medicine, Houston, TX, ²MD Anderson Cancer Center, Bellaire, TX, ³UT MD Anderson Cancer Center, Houston, TX, ⁴The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁵MD Anderson Cancer Center, Houston, TX, ⁶The Univesrity of Texas MD Andesron Cancer Center, Pearland, TX
Background/Purpose: Immune checkpoint inhibitors (ICIs) are revolutionizing cancer treatment. However, ICIs often lead to immune-related adverse events (irAEs). Approximately 5% of patients treated with ICIs…

« Previous Page
1
…
8
9
10
11
12
…
58
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].